CCG-222740|cas:1922098-69-8|西域试剂

CCG-222740,99.85%

产品编号：Bellancom-121750| CAS NO：1922098-69-8| 分子式：C₂₃H₁₉ClF₂N₂O₃| 分子量：444.86

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-121750	￥3100.00	杭州北京（现货）
Bellancom-121750	￥4900.00	杭州北京（现货）
Bellancom-121750	￥8700.00	杭州北京（现货）
Bellancom-121750	￥14000.00	杭州北京（现货）
Bellancom-121750	￥19000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CCG-222740

产品介绍

CCG-222740 是一种口服有效的，选择性 Rho/MRTF 途径抑制剂。CCG-222740 也是有效的 α-平滑肌肌动蛋白蛋白表达抑制剂。CCG-222740 有效减少皮肤纤维化并阻止黑色素瘤转移。

生物活性

CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis.

体外研究

CCG-222740 (10, 20 μM; for 72 hours) increases the protein levels of p27 and decreases cyclin D1. CCG-222740 decreases cell viability of CAFs, with an IC₅₀ of ~10 μM.
CCG-222740 (10, 25 μM) is potent at decreasing αSMA protein expression in human conjunctival fibroblasts.
CCG-222740 has an IC₅₀ of 5 μM in a fibroblast-mediated collagen contraction assay, and it is less cytotoxic.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis

Cell Line:	Cancer associated fibroblasts (CAFs)
Concentration:	10, 20 μM
Incubation Time:	72 hours
Result:	Increased the protein levels of p27 and decreased cyclin D1.

体内研究
(In Vivo)

CCG-222740 (oral gavage; 100 mg/kg/day for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	KC mice (LSL-Kras^G12D/+; Pdx-1-Cre) of age at 9 weeks
Dosage:	100 mg/kg
Administration:	Oral gavage; daily; for 7 days
Result:	Reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice.

体内研究

CCG-222740 (oral gavage; 100 mg/kg/day for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	KC mice (LSL-Kras^G12D/+; Pdx-1-Cre) of age at 9 weeks
Dosage:	100 mg/kg
Administration:	Oral gavage; daily; for 7 days
Result:	Reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice.

体内研究

CCG-222740 (oral gavage; 100 mg/kg/day for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	KC mice (LSL-Kras^G12D/+; Pdx-1-Cre) of age at 9 weeks
Dosage:	100 mg/kg
Administration:	Oral gavage; daily; for 7 days
Result:	Reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (280.99 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2479 mL	11.2395 mL	22.4790 mL
5 mM	0.4496 mL	2.2479 mL	4.4958 mL
10 mM	0.2248 mL	1.1239 mL	2.2479 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.25 mg/mL (5.06 mM); Clear solution

此方案可获得 ≥ 2.25 mg/mL (5.06 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.25 mg/mL (5.06 mM); Suspended solution; Need ultrasonic

此方案可获得 2.25 mg/mL (5.06 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.25 mg/mL (5.06 mM); Clear solution

此方案可获得 ≥ 2.25 mg/mL (5.06 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 22.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。